Tvardi Therapeutics is trading 6.49% higher at $0.92 on November 6, with no company-specific announcement identified to explain the move. - Its latest listed company releases predate November 6. - The supplied sector update reports XBI up 2.01%, alongside Moderna’s strong quarterly results and raised 2026 outlook. - Broader biotech strength may be contributing, but does not establish a direct cause for Tvardi’s larger gain.